|1.||Ochi, Yusuke: 3 articles (12/2007 - 02/2004)|
|2.||Feit, Kevie: 3 articles (09/2006 - 08/2005)|
|3.||De Jager, Robert L: 3 articles (09/2006 - 07/2002)|
|4.||Rowinsky, Eric K: 3 articles (08/2005 - 07/2003)|
|5.||Oguma, Toshihiro: 3 articles (04/2005 - 03/2004)|
|6.||Boven, E: 3 articles (10/2004 - 09/2002)|
|7.||Cheverton, P: 3 articles (10/2004 - 01/2000)|
|8.||De Jager, R: 3 articles (01/2004 - 01/2000)|
|9.||Kuga, Hiroshi: 2 articles (12/2007 - 04/2005)|
|10.||Shiose, Yoshinobu: 2 articles (12/2007 - 04/2005)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2003 - "Therefore, DX-8951f was highly effective against primary and metastatic growth in this very difficult-to-treat disease and showed significantly higher efficacy than gemcitabine, the standard treatment of pancreatic cancer. "
09/20/2006 - "Exatecan plus gemcitabine was not superior to gemcitabine alone with respect to overall survival in the first-line treatment of advanced pancreatic cancer."
09/01/2004 - "However, several agents show promising results in other GI malignancies, eg, rubitecan and exatecan in pancreatic cancer. "
01/01/2003 - "We determined the antitumor and antimetastatic efficacy of the camptothecin analogue DX-8951f in an orthotopic metastatic mouse model of pancreatic cancer. "
09/20/2006 - "A multicenter, randomized, phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted. "
01/01/2003 - "DX-8951f was significantly effective in a dose-response manner on the BxPC-3 primary tumor. "
08/01/2005 - "In pre-clinical studies, high levels and prolonged retention of conjugated DX-8951 (carrier-bound DX-8951) have been observed in tumor tissues following DE-310 administration. "
01/01/2003 - "The DX-8951f studies included both an early and advanced cancer model. "
08/01/2005 - "Concentrations of conjugated DX-8951, DX-8951 and G-DX-8951 were in general similar in tumor and relevant normal tissue samples and preferential accumulation of DE-310, DX-8951 and G-DX-8951 in human tumor tissues was not observed. "
08/01/2005 - "DX-8951 and G-DX-8951 (glycyl-DX-8951) exerting anti-tumor activity in vivo are released from DE-310 by enzymatic cleavage of the spacer. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
10/15/2002 - "In conclusion, this study shows that DX-8951f is highly potent in vitro and highly effective in experimental human ovarian cancer in vivo. "
09/09/2002 - "Therefore, we selected a subline of the human ovarian cancer cell line A2780 for resistance against DX-8951f to investigate possible mechanisms of resistance. "
10/01/2004 - "Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. "
10/15/2002 - "In the OVCAR-3 human ovarian cancer model, DX-8951f showed considerably greater activity than topotecan (P<0.01). "
10/15/2002 - "We determined the activity of DX-8951f in experimental human colon cancer and ovarian cancer, being tumor types sensitive to camptothecins. "
09/01/2003 - "A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma."
08/01/2005 - "A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma. "
09/01/2003 - "The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma. "
09/01/2003 - "Exatecan mesylate had moderate activity in patients with anthracycline-refractory and taxane-refractory, metastatic breast carcinoma. "
01/01/2004 - "A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum."
08/01/1995 - "The antitumor activity of three doses of DX-8951f administered i.v. at 4-day intervals against human gastric adenocarcinoma SC-6 xenografts was greater than that of CPT-11 or SK&F 10486-A. "
01/01/1998 - "Against both gastric adenocarcinoma SC-6 and its CPT-11-resistant variant, SC-6/CPT-11, DX-8951f demonstrated superior antitumor activity and antitumor activity over a broader range of doses than did CPT-11, SK&F104864 (hycamtin, topotecan) and GG-211 (GI147211). "
|1.||exatecan (DX 8951f)
|8.||Type I DNA Topoisomerases (Topoisomerase I)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|3.||Nebulizers and Vaporizers (Inhaler)